Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jul 12:6:1121.
doi: 10.12688/f1000research.11820.1. eCollection 2017.

Progress toward an integrated understanding of Parkinson's disease

Affiliations
Review

Progress toward an integrated understanding of Parkinson's disease

Maxime W C Rousseaux et al. F1000Res. .

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting over 10 million individuals worldwide. While numerous effective symptomatic treatments are currently available, no curative or disease-modifying therapies exist. An integrated, comprehensive understanding of PD pathogenic mechanisms will likely address this unmet clinical need. Here, we highlight recent progress in PD research with an emphasis on promising translational findings, including (i) advances in our understanding of disease susceptibility, (ii) improved knowledge of cellular dysfunction, and (iii) insights into mechanisms of spread and propagation of PD pathology. We emphasize connections between these previously disparate strands of PD research and the development of an emerging systems-level understanding that will enable the next generation of PD therapeutics.

Keywords: PD; Parkinson's disease; Parkinson's disease genetics; neurodegenerative disorders; α-Synuclein.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Maxime W.C. Rousseaux and Joshua M. Shulman declare that they have no disclosures. Joseph Jankovic has received research or training grants and/or has served as a consultant for the Michael J. Fox Foundation for Parkinson’s Research, Prothena Biosciences Inc, and Teva Pharmaceutical Industries Ltd.No competing interests were disclosed.No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Putting the Parkinson’s disease (PD) puzzle together.
Three pieces of the “PD puzzle” covered in this short review are highlighted within the context of the brain. Additional elements remain to be fully elucidated. The integrated, systems-level understanding of PD that emerges from understanding how these components fit together will likely accelerate therapeutic advances. α-Syn, α-synuclein.

References

    1. Poewe W, Seppi K, Tanner CM, et al. : Parkinson disease. Nat Rev Dis Primers. 2017;3:17013. 10.1038/nrdp.2017.13 - DOI - PubMed
    2. F1000 Recommendation

    1. Postuma RB, Berg D, Stern M, et al. : MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591–601. 10.1002/mds.26424 - DOI - PubMed
    1. Lotia M, Jankovic J: New and emerging medical therapies in Parkinson’s disease. Expert Opin Pharmacother. 2016;17(7):895–909. 10.1517/14656566.2016.1149163 - DOI - PubMed
    1. Parkinson J: An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223–36; discussion 222. 10.1176/jnp.14.2.223 - DOI - PubMed
    1. Jankovic J: Movement disorders in 2016: progress in Parkinson disease and other movement disorders. Nat Rev Neurol. 2017;13(2):76–8. 10.1038/nrneurol.2016.204 - DOI - PubMed

LinkOut - more resources